About BlueRock Therapeutics
BlueRock focuses on stem cell research to regenerate heart muscles after a heart attack, and to develop therapies for Parkinson’s disease.
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock’s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
Founder: Gordon Keller and Lorenz Studer
CEO: Emile Nuwaysir
43 articles with BlueRock Therapeutics
BlueRock Therapeutics announced today that Emile Nuwaysir , Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021 . Current Chief Scientific Officer Seth Ettenberg , Ph.D., will assume the role of President an CEO.
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease
BlueRock Therapeutics LP announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson's disease (PD).
6/14/2021A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials.
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the dose administration for the first patient in a Phase 1, open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson's disease.
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
ClearPoint Neuro, Inc. today congratulates BlueRock Therapeutics on the dose administration for the first patient in a Phase 1, open-label study.
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (PD)."
BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team.
Here’s a look at the top three companies from the “Top 20 Life Science Startups to Watch in 2018.”
BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 in Carlsbad, Calif.
Another successful outcome from a Versant-created company in a breakthrough field
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.
Under the terms of the acquisition, Bayer is buying the rest of the company for $240 million up front with an additional $360 million in various development milestones. This will correspond with the company’s value of about $1 billion.
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, announced that the company will present at the following upcoming conferences.
BlueRock Therapeutics, LP announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.